Trial
NCT02780700
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Colorectal Neoplasms
Intervention
Nintedanib
Why stopped
Substance discontinued
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-03